Morphotek gains $40M in fourth venture round

Morphotek has raised $40 million in fourth round of funding to advance its therapeutic monoclonal antibodies. Morphotek's lead antibody, MORAb-003, specifically targets the folate receptor alpha, a cell surface receptor over-expressed on ovarian, breast, colorectal, lung and renal tumors. Investor Growth Capital of New York led the round for the Exton, PA-based developer.

- see the release for more information

PLUS: Amyris Biotechnologies has gained $20 million in first-round venture financing from a group that includes Khosla Ventures, which is operated by Sun co-founder Vinod Khosla. Kleiner Perkins Caufield & Byers also participated. John G. Melo, previously president of U.S. Fuels Operations, was named CEO. Amyris is using synthetic biology techniques to develop rare chemicals for use in pharmaceuticals and energy. Release and Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.